Latest Therapeutics News

Page 15 of 90
IDT Australia boosts its FY26 revenue guidance to $16.8 million, anticipating a substantial narrowing of EBITDA losses to under $1 million, driven by strong demand and cost efficiencies.
Ada Torres
Ada Torres
21 July 2026
AFT Pharmaceuticals has received tentative US FDA approval for its Scomara cream to treat Facial Angiofibromas in Tuberous Sclerosis, but US commercialisation is postponed until 2029 due to orphan drug exclusivity. The approval bolsters regulatory prospects in other key markets where AFT anticipates competitive advantages.
Victor Sage
Victor Sage
21 July 2026
PYC Therapeutics reports durable retinal gene expression and visual improvements from its PYC-001 candidate in Autosomal Dominant Optic Atrophy, supporting longer dosing intervals and expansion into glaucoma research.
Ada Torres
Ada Torres
21 July 2026
Telix Pharmaceuticals reported a 21% year-on-year revenue jump to US$247 million in Q2 2026, buoyed by strong Precision Medicine sales and a new Regeneron partnership. The company also secured FDA alignment on a pivotal prostate cancer trial and expanded its manufacturing footprint.
Ada Torres
Ada Torres
21 July 2026
Actinogen Medical’s phase 2 trial of Xanamem in major depressive disorder with cognitive impairment reveals meaningful antidepressant effects, published in the British Journal of Psychiatry. The drug was safe and well-tolerated but did not improve cognition.
Ada Torres
Ada Torres
20 July 2026
Entropy Neurodynamics has expanded its global intellectual property portfolio with a South African patent for psilocybin-based fibromyalgia treatment, covering broad therapeutic methods and extending protection to 2043.
Ada Torres
Ada Torres
20 July 2026
Neurizon Therapeutics has completed enrolment for Regimen I of its HEALEY ALS Platform Trial in under five months, speeding up topline data release to late Q2 2027 and materially de-risking its lead clinical program.
Ada Torres
Ada Torres
17 July 2026
Dimerix has acquired DMX-652, a Phase 2-ready oral drug candidate targeting acute kidney injury, expanding its renal disease portfolio. The acquisition includes patent rights, an FDA-approved trial protocol, and funding to initiate clinical development.
Ada Torres
Ada Torres
17 July 2026
Chimeric Therapeutics reports encouraging interim data from its Phase 1/2 trial of CHM CDH17 CAR-T therapy, with tumour shrinkage up to 40% and stable disease maintained for months at the highest dose level.
Ada Torres
Ada Torres
16 July 2026
Microba Life Sciences has delivered robust FY26 growth in its core microbiome testing business, with revenues up 92% year-on-year and a new GI Navigator product set for launch in September 2026. The company also announced a $7 million annualised cost reduction program as it advances towards cashflow break-even.
Ada Torres
Ada Torres
16 July 2026
Nexalis Therapeutics has issued share rights to directors in lieu of fees, with vesting contingent on successful Phase 2 clinical trial completion, aiming to conserve cash for ongoing drug development.
Ada Torres
Ada Torres
14 July 2026
INOVIQ Ltd has revealed significant sample quality problems in its EXO-OC ovarian cancer diagnostic study, prompting a technical review and a refined development approach while maintaining its dual commercialisation strategy.
Ada Torres
Ada Torres
14 July 2026

Browse the archive

Full archive